title: [The effect of protease inhibitors in shock].
abstract: Protease inhibitors, such as ulinastatin and gabexate mesilate, are widely used for the patients in shock state. The purpose of this study was to evaluate the effects of these protease inhibitors on renal protection and coagulofibrinolytic disorders. The obtained results were as follows: 1. Ulinastatin studies. 1) Beta 2-microglobulin (BMG) excretion and N-acetyl-beta-D-glucosaminidase (NAG) activity in urine were increased in cases of emergency operation (10 patients) compared with elective operation (38 patients). 2) In canine experimental model of renal ischemia, ulinastatin significantly improved urine volume and urine NAG levels. 3) Administration of ulinastatin suppressed urine NAG level in 12 patients, but BMG level did not significantly change. 2. Gabexate mesilate (FOY) studies. 1) All patients in shock state showed coagulofibrinolytic disorders. Especially remarkable hypercoagulability was observed in 21 patients. 2) FOY suppressed platelet aggregation and the release of beta-thromboglobulin and platelet factor 4. 3) In 24 patients, administration of FOY markedly increased the antithrombin III levels in early postoperative period. 4) Fibrinolytic system was not affected any significant changes with administration of FOY.
  
  
  CONCLUSIONS
  Our results suggested that protease inhibitors are useful for management of the patients in shock state.
authors.affiliation: First Department of Surgery, Fukushima Medical College, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Inoue
authors.forename: A
authors.initials: A
authors.lastname: Usuba
authors.forename: Y
authors.initials: Y
authors.lastname: Endo
authors.forename: S
authors.initials: S
authors.lastname: Terashima
authors.forename: M
authors.initials: M
authors.lastname: Watanabe
authors.forename: J
authors.initials: J
authors.lastname: Miura
authors.forename: R
authors.initials: R
authors.lastname: Motoki
mesh_terms: D000818:Animals; D001778:Blood Coagulation Disorders / Q000188:drug therapy; D004285:Dogs; D016670:Gabexate; D006023:Glycoproteins / Q000627:therapeutic use*; D006146:Guanidines / Q000627:therapeutic use*; D006801:Humans; D007668:Kidney / Q000187:drug effects; D015842:Serine Proteinase Inhibitors / Q000627:therapeutic use*; D012769:Shock / Q000188:drug therapy* / Q000503:physiopathology; D014361:Trypsin Inhibitors / Q000627:therapeutic use*
chemical_list: D006023:Glycoproteins; D006146:Guanidines; D015842:Serine Proteinase Inhibitors; D014361:Trypsin Inhibitors; D016670:Gabexate; C028665:urinastatin